Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study
This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan. In total, 1,486 adult patients newly diagnosed with BPH and...
Gespeichert in:
| Veröffentlicht in: | PloS one 2015-03, Vol.10 (3), p.e0119694-e0119694 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0119694 |
|---|---|
| container_issue | 3 |
| container_start_page | e0119694 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Hsieh, Teng-Fu Yang, Yu-Wan Lee, Shang-Sen Lin, Tien-Huang Liu, Hsin-Ho Tsai, Tsung-Hsun Chen, Chi-Cheng Huang, Yung-Sung Lee, Ching-Chih |
| description | This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan.
In total, 1,486 adult patients newly diagnosed with BPH and who used 5-alpha-reductase inhibitors were recruited as the study cohort, along with 9,995 subjects who did not use 5-alpha-reductase inhibitors as a comparison cohort from 2003 to 2008. Each patient was monitored for 5 years, and those who subsequently had cardiovascular diseases were identified. A Cox proportional hazards model was used to compare the risk of cardiovascular diseases between the study and comparison cohorts after adjusting for possible confounding risk factors.
The patients who received 5-alpha-reductase inhibitor therapy had a lower cumulative rate of cardiovascular diseases than those who did not receive 5-alpha-reductase inhibitor therapy during the 5-year follow-up period (8.4% vs. 11.2%, P=0.003). In subgroup analysis, the 5-year cardiovascular event hazard ratio (HR) was lower among the patients older than 65 years with 91 to 365 cumulative defined daily dose (cDDD) 5-alpha-reductase inhibitor use (HR=0.63, 95% confidence interval (CI) 0.42 to 0.92; P=0.018), however there was no difference among the patients with 28 to 90 and more than 365 cDDD 5-alpha-reductase inhibitor use (HR=1.14, 95% CI 0.77 to 1.68; P=0.518 and HR=0.83, 95% CI 0.57 to 1.20; P=0.310, respectively).
5-alpha-reductase inhibitor therapy did not increase the risk of cardiovascular events in the BPH patients in 5 years of follow-up. Further mechanistic research is needed. |
| doi_str_mv | 10.1371/journal.pone.0119694 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1666309695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A422370731</galeid><doaj_id>oai_doaj_org_article_07e3c123b9864595adde063d29f101df</doaj_id><sourcerecordid>A422370731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-3183fcd96a476433dacfbc2bdbbbac1921fc4b5d462d578f772ca66a18c173bf3</originalsourceid><addsrcrecordid>eNqNk9tu1DAQhiMEoqXwBggiISG4yBLbiZNwgVRVHFaqVAkot9bEh42LNw62s2VfhyfF6abVLuoF8kWs8Tf_eP54kuQ5yheIVOjdlR1dD2Yx2F4ucoQa2hQPkmPUEJxRnJOHe_uj5In3V3lekprSx8kRLuucFIQcJ38uvUytSssMzNBB5qQYeYAY1H2nWx2s86nQIu1tiCHu5HQWOpk67X9OmRyc0HYDno8GXGT9hPgIpwMELfvg02sdurSVvV7FoLM-QJBptx2kGwx4De9TSJXeyGwro4SyxtjrbBxSH0axfZo8UmC8fDZ_T5LLTx-_n33Jzi8-L89OzzNOGxwygmqiuGgoFBWNvQngquW4FW3bAkcNRooXbSkKikVZ1aqqMAdKAdUcVaRV5CR5udMdjPVsttczRCkleXS3jMRyRwgLV2xweg1uyyxodhOwbsXABc2NZHklCUeYtE1Ni7IpQQiZUyJwo1COxFTtw1xtbNdS8OiTA3MgenjS646t7IYVpMJFMV3mzSzg7K9R-sDW2nNpDPTSjrt7N3WFbtBX_6D3dzdTK4gN6F7ZWJdPouy0wJhUeUVQpBb3UHEJudY8vkWlY_wg4e1BQmSC_B1WMHrPlt--_j978eOQfb3HdhJM6Lw1Y9C294dgsQN5fHneSXVnMsrZNEq3brBplNg8SjHtxf4Puku6nR3yF9J0HGE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1666309695</pqid></control><display><type>article</type><title>Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hsieh, Teng-Fu ; Yang, Yu-Wan ; Lee, Shang-Sen ; Lin, Tien-Huang ; Liu, Hsin-Ho ; Tsai, Tsung-Hsun ; Chen, Chi-Cheng ; Huang, Yung-Sung ; Lee, Ching-Chih</creator><contributor>Chuu, Chih-Pin</contributor><creatorcontrib>Hsieh, Teng-Fu ; Yang, Yu-Wan ; Lee, Shang-Sen ; Lin, Tien-Huang ; Liu, Hsin-Ho ; Tsai, Tsung-Hsun ; Chen, Chi-Cheng ; Huang, Yung-Sung ; Lee, Ching-Chih ; Chuu, Chih-Pin</creatorcontrib><description>This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan.
In total, 1,486 adult patients newly diagnosed with BPH and who used 5-alpha-reductase inhibitors were recruited as the study cohort, along with 9,995 subjects who did not use 5-alpha-reductase inhibitors as a comparison cohort from 2003 to 2008. Each patient was monitored for 5 years, and those who subsequently had cardiovascular diseases were identified. A Cox proportional hazards model was used to compare the risk of cardiovascular diseases between the study and comparison cohorts after adjusting for possible confounding risk factors.
The patients who received 5-alpha-reductase inhibitor therapy had a lower cumulative rate of cardiovascular diseases than those who did not receive 5-alpha-reductase inhibitor therapy during the 5-year follow-up period (8.4% vs. 11.2%, P=0.003). In subgroup analysis, the 5-year cardiovascular event hazard ratio (HR) was lower among the patients older than 65 years with 91 to 365 cumulative defined daily dose (cDDD) 5-alpha-reductase inhibitor use (HR=0.63, 95% confidence interval (CI) 0.42 to 0.92; P=0.018), however there was no difference among the patients with 28 to 90 and more than 365 cDDD 5-alpha-reductase inhibitor use (HR=1.14, 95% CI 0.77 to 1.68; P=0.518 and HR=0.83, 95% CI 0.57 to 1.20; P=0.310, respectively).
5-alpha-reductase inhibitor therapy did not increase the risk of cardiovascular events in the BPH patients in 5 years of follow-up. Further mechanistic research is needed.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0119694</identifier><identifier>PMID: 25803433</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>5-alpha Reductase Inhibitors - adverse effects ; 5-alpha Reductase Inhibitors - therapeutic use ; Aged ; Analysis of Variance ; Benign ; Cardiac patients ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - chemically induced ; Cardiovascular Diseases - epidemiology ; Care and treatment ; Cohort Studies ; Confidence intervals ; Diseases ; Follow-Up Studies ; Genital diseases ; Hazard identification ; Health care policy ; Health risks ; Heart diseases ; Humans ; Hyperplasia ; Inhibitors ; Male ; Medical research ; Middle Aged ; Mortality ; National health insurance ; Online databases ; Patients ; Population studies ; Proportional Hazards Models ; Prostate ; Prostate cancer ; Prostatic Hyperplasia - drug therapy ; Prostatic Hyperplasia - epidemiology ; Reductase ; Risk analysis ; Risk Assessment ; Risk factors ; Statistical models ; Studies ; Subgroups ; Taiwan - epidemiology ; Therapy</subject><ispartof>PloS one, 2015-03, Vol.10 (3), p.e0119694-e0119694</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Hsieh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Hsieh et al 2015 Hsieh et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-3183fcd96a476433dacfbc2bdbbbac1921fc4b5d462d578f772ca66a18c173bf3</citedby><cites>FETCH-LOGICAL-c692t-3183fcd96a476433dacfbc2bdbbbac1921fc4b5d462d578f772ca66a18c173bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372445/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372445/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2097,2916,23848,27906,27907,53773,53775,79350,79351</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25803433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Chuu, Chih-Pin</contributor><creatorcontrib>Hsieh, Teng-Fu</creatorcontrib><creatorcontrib>Yang, Yu-Wan</creatorcontrib><creatorcontrib>Lee, Shang-Sen</creatorcontrib><creatorcontrib>Lin, Tien-Huang</creatorcontrib><creatorcontrib>Liu, Hsin-Ho</creatorcontrib><creatorcontrib>Tsai, Tsung-Hsun</creatorcontrib><creatorcontrib>Chen, Chi-Cheng</creatorcontrib><creatorcontrib>Huang, Yung-Sung</creatorcontrib><creatorcontrib>Lee, Ching-Chih</creatorcontrib><title>Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan.
In total, 1,486 adult patients newly diagnosed with BPH and who used 5-alpha-reductase inhibitors were recruited as the study cohort, along with 9,995 subjects who did not use 5-alpha-reductase inhibitors as a comparison cohort from 2003 to 2008. Each patient was monitored for 5 years, and those who subsequently had cardiovascular diseases were identified. A Cox proportional hazards model was used to compare the risk of cardiovascular diseases between the study and comparison cohorts after adjusting for possible confounding risk factors.
The patients who received 5-alpha-reductase inhibitor therapy had a lower cumulative rate of cardiovascular diseases than those who did not receive 5-alpha-reductase inhibitor therapy during the 5-year follow-up period (8.4% vs. 11.2%, P=0.003). In subgroup analysis, the 5-year cardiovascular event hazard ratio (HR) was lower among the patients older than 65 years with 91 to 365 cumulative defined daily dose (cDDD) 5-alpha-reductase inhibitor use (HR=0.63, 95% confidence interval (CI) 0.42 to 0.92; P=0.018), however there was no difference among the patients with 28 to 90 and more than 365 cDDD 5-alpha-reductase inhibitor use (HR=1.14, 95% CI 0.77 to 1.68; P=0.518 and HR=0.83, 95% CI 0.57 to 1.20; P=0.310, respectively).
5-alpha-reductase inhibitor therapy did not increase the risk of cardiovascular events in the BPH patients in 5 years of follow-up. Further mechanistic research is needed.</description><subject>5-alpha Reductase Inhibitors - adverse effects</subject><subject>5-alpha Reductase Inhibitors - therapeutic use</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Benign</subject><subject>Cardiac patients</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - chemically induced</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Care and treatment</subject><subject>Cohort Studies</subject><subject>Confidence intervals</subject><subject>Diseases</subject><subject>Follow-Up Studies</subject><subject>Genital diseases</subject><subject>Hazard identification</subject><subject>Health care policy</subject><subject>Health risks</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Inhibitors</subject><subject>Male</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>National health insurance</subject><subject>Online databases</subject><subject>Patients</subject><subject>Population studies</subject><subject>Proportional Hazards Models</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Prostatic Hyperplasia - epidemiology</subject><subject>Reductase</subject><subject>Risk analysis</subject><subject>Risk Assessment</subject><subject>Risk factors</subject><subject>Statistical models</subject><subject>Studies</subject><subject>Subgroups</subject><subject>Taiwan - epidemiology</subject><subject>Therapy</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tu1DAQhiMEoqXwBggiISG4yBLbiZNwgVRVHFaqVAkot9bEh42LNw62s2VfhyfF6abVLuoF8kWs8Tf_eP54kuQ5yheIVOjdlR1dD2Yx2F4ucoQa2hQPkmPUEJxRnJOHe_uj5In3V3lekprSx8kRLuucFIQcJ38uvUytSssMzNBB5qQYeYAY1H2nWx2s86nQIu1tiCHu5HQWOpk67X9OmRyc0HYDno8GXGT9hPgIpwMELfvg02sdurSVvV7FoLM-QJBptx2kGwx4De9TSJXeyGwro4SyxtjrbBxSH0axfZo8UmC8fDZ_T5LLTx-_n33Jzi8-L89OzzNOGxwygmqiuGgoFBWNvQngquW4FW3bAkcNRooXbSkKikVZ1aqqMAdKAdUcVaRV5CR5udMdjPVsttczRCkleXS3jMRyRwgLV2xweg1uyyxodhOwbsXABc2NZHklCUeYtE1Ni7IpQQiZUyJwo1COxFTtw1xtbNdS8OiTA3MgenjS646t7IYVpMJFMV3mzSzg7K9R-sDW2nNpDPTSjrt7N3WFbtBX_6D3dzdTK4gN6F7ZWJdPouy0wJhUeUVQpBb3UHEJudY8vkWlY_wg4e1BQmSC_B1WMHrPlt--_j978eOQfb3HdhJM6Lw1Y9C294dgsQN5fHneSXVnMsrZNEq3brBplNg8SjHtxf4Puku6nR3yF9J0HGE</recordid><startdate>20150324</startdate><enddate>20150324</enddate><creator>Hsieh, Teng-Fu</creator><creator>Yang, Yu-Wan</creator><creator>Lee, Shang-Sen</creator><creator>Lin, Tien-Huang</creator><creator>Liu, Hsin-Ho</creator><creator>Tsai, Tsung-Hsun</creator><creator>Chen, Chi-Cheng</creator><creator>Huang, Yung-Sung</creator><creator>Lee, Ching-Chih</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150324</creationdate><title>Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study</title><author>Hsieh, Teng-Fu ; Yang, Yu-Wan ; Lee, Shang-Sen ; Lin, Tien-Huang ; Liu, Hsin-Ho ; Tsai, Tsung-Hsun ; Chen, Chi-Cheng ; Huang, Yung-Sung ; Lee, Ching-Chih</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-3183fcd96a476433dacfbc2bdbbbac1921fc4b5d462d578f772ca66a18c173bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>5-alpha Reductase Inhibitors - adverse effects</topic><topic>5-alpha Reductase Inhibitors - therapeutic use</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Benign</topic><topic>Cardiac patients</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - chemically induced</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Care and treatment</topic><topic>Cohort Studies</topic><topic>Confidence intervals</topic><topic>Diseases</topic><topic>Follow-Up Studies</topic><topic>Genital diseases</topic><topic>Hazard identification</topic><topic>Health care policy</topic><topic>Health risks</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Inhibitors</topic><topic>Male</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>National health insurance</topic><topic>Online databases</topic><topic>Patients</topic><topic>Population studies</topic><topic>Proportional Hazards Models</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Prostatic Hyperplasia - epidemiology</topic><topic>Reductase</topic><topic>Risk analysis</topic><topic>Risk Assessment</topic><topic>Risk factors</topic><topic>Statistical models</topic><topic>Studies</topic><topic>Subgroups</topic><topic>Taiwan - epidemiology</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsieh, Teng-Fu</creatorcontrib><creatorcontrib>Yang, Yu-Wan</creatorcontrib><creatorcontrib>Lee, Shang-Sen</creatorcontrib><creatorcontrib>Lin, Tien-Huang</creatorcontrib><creatorcontrib>Liu, Hsin-Ho</creatorcontrib><creatorcontrib>Tsai, Tsung-Hsun</creatorcontrib><creatorcontrib>Chen, Chi-Cheng</creatorcontrib><creatorcontrib>Huang, Yung-Sung</creatorcontrib><creatorcontrib>Lee, Ching-Chih</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsieh, Teng-Fu</au><au>Yang, Yu-Wan</au><au>Lee, Shang-Sen</au><au>Lin, Tien-Huang</au><au>Liu, Hsin-Ho</au><au>Tsai, Tsung-Hsun</au><au>Chen, Chi-Cheng</au><au>Huang, Yung-Sung</au><au>Lee, Ching-Chih</au><au>Chuu, Chih-Pin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-03-24</date><risdate>2015</risdate><volume>10</volume><issue>3</issue><spage>e0119694</spage><epage>e0119694</epage><pages>e0119694-e0119694</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan.
In total, 1,486 adult patients newly diagnosed with BPH and who used 5-alpha-reductase inhibitors were recruited as the study cohort, along with 9,995 subjects who did not use 5-alpha-reductase inhibitors as a comparison cohort from 2003 to 2008. Each patient was monitored for 5 years, and those who subsequently had cardiovascular diseases were identified. A Cox proportional hazards model was used to compare the risk of cardiovascular diseases between the study and comparison cohorts after adjusting for possible confounding risk factors.
The patients who received 5-alpha-reductase inhibitor therapy had a lower cumulative rate of cardiovascular diseases than those who did not receive 5-alpha-reductase inhibitor therapy during the 5-year follow-up period (8.4% vs. 11.2%, P=0.003). In subgroup analysis, the 5-year cardiovascular event hazard ratio (HR) was lower among the patients older than 65 years with 91 to 365 cumulative defined daily dose (cDDD) 5-alpha-reductase inhibitor use (HR=0.63, 95% confidence interval (CI) 0.42 to 0.92; P=0.018), however there was no difference among the patients with 28 to 90 and more than 365 cDDD 5-alpha-reductase inhibitor use (HR=1.14, 95% CI 0.77 to 1.68; P=0.518 and HR=0.83, 95% CI 0.57 to 1.20; P=0.310, respectively).
5-alpha-reductase inhibitor therapy did not increase the risk of cardiovascular events in the BPH patients in 5 years of follow-up. Further mechanistic research is needed.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25803433</pmid><doi>10.1371/journal.pone.0119694</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-03, Vol.10 (3), p.e0119694-e0119694 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1666309695 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | 5-alpha Reductase Inhibitors - adverse effects 5-alpha Reductase Inhibitors - therapeutic use Aged Analysis of Variance Benign Cardiac patients Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - chemically induced Cardiovascular Diseases - epidemiology Care and treatment Cohort Studies Confidence intervals Diseases Follow-Up Studies Genital diseases Hazard identification Health care policy Health risks Heart diseases Humans Hyperplasia Inhibitors Male Medical research Middle Aged Mortality National health insurance Online databases Patients Population studies Proportional Hazards Models Prostate Prostate cancer Prostatic Hyperplasia - drug therapy Prostatic Hyperplasia - epidemiology Reductase Risk analysis Risk Assessment Risk factors Statistical models Studies Subgroups Taiwan - epidemiology Therapy |
| title | Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A40%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%205-alpha-reductase%20inhibitors%20did%20not%20increase%20the%20risk%20of%20cardiovascular%20diseases%20in%20patients%20with%20benign%20prostate%20hyperplasia:%20a%20five-year%20follow-up%20study&rft.jtitle=PloS%20one&rft.au=Hsieh,%20Teng-Fu&rft.date=2015-03-24&rft.volume=10&rft.issue=3&rft.spage=e0119694&rft.epage=e0119694&rft.pages=e0119694-e0119694&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0119694&rft_dat=%3Cgale_plos_%3EA422370731%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1666309695&rft_id=info:pmid/25803433&rft_galeid=A422370731&rft_doaj_id=oai_doaj_org_article_07e3c123b9864595adde063d29f101df&rfr_iscdi=true |